CHA Biotech said on the 16th that it received a 100 billion won investment from HANWHA GENERAL INSURANCE and Hanwha Life Insurance. Through a third-party allotment paid-in capital increase, HANWHA GENERAL INSURANCE invested 70 billion won and Hanwha Life Insurance invested 30 billion won. The goal is to expand synergies between healthcare and insurance.
CHA Biotech Group, HANWHA GENERAL INSURANCE and Hanwha Life Insurance will develop various health programs tailored to the customer life cycle. Representative examples include premium healthcare for women and health management for insurance customers. They will apply artificial intelligence (AI) and data to the health programs.
The medical, biotech and healthcare technologies of CHA Biotech Group will be combined with Hanwha's insurance and financial business infrastructure. A CHA Biotech Group official said, "We stabilized our financial structure by attracting a strategic investor," and added, "We will build alliances with information technology (IT) and the financial industry."